Search This Blog

Monday, August 10, 2020

Esperion Therapeutics EPS beats by $2.09, beats on revenue

Esperion Therapeutics (NASDAQ:ESPR): Q2 GAAP EPS of $4.32 beats by $2.09.
Revenue of $212.24M (+21557.1% Y/Y) beats by $64.27M.
Shares +0.94%.
Press Release

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)